HMOX1 and Parkinson disease: An upregulation of Hmox1 and an increased level of UCB in the serum have been reported in the early clinical stages of PD (Hoehn and Yahr Stage ≤ 3) [33,34], reversing with the progression of severity in the clinical setting.